nach oben

European Radiology

Erschienen in:

01.05.2010 | Urogenital

Imaging of prostate cancer local recurrences: why and how?

verfasst von: Olivier Rouvière, Thierry Vitry, Denis Lyonnet

Erschienen in: European Radiology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

Because prostate cancer local recurrences can be efficiently treated by salvage therapies, it becomes critical to detect them early.

Methods

The first alert is the rise of the prostate specific antigen (PSA) level after the post-treatment nadir, which can correspond to a distant recurrence, a local recurrence or both. This so-called biochemical failure (BF) is defined as PSA level > 0.2 ng/ml after radical prostatectomy (RP) and PSA level > nadir + 2 ng/ml after radiotherapy. There is no consensual definition of BF after cryotherapy, high-intensity focused ultrasound (HIFU) ablation or brachytherapy.

Results

Local recurrences after RP are treated by radiotherapy, those after radiotherapy by RP, cryotherapy, brachytherapy or HIFU ablation. Recurrences after cryotherapy or HIFU ablation can be treated by a second session or radiotherapy. Recurrences after brachytherapy are difficult to treat. In patients with BF, MRI can detect local recurrences, whatever the initial treatment was. Dynamic contrast-enhanced MRI seems particularly accurate. The role of spectroscopy remains controversial. Ultrasound-based techniques are less accurate, but this may change with the advent of ultrasonic contrast media.

Conclusion

These recent advances in imaging may improve the outcome of salvage therapies (by improving patient selection and treatment targeting) and should open the way to focal salvage treatments in the near future.

Naito S (2005) Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol 35:365–374CrossRefPubMed

Nguyen PL, D’Amico AV, Lee AK, Suh WW (2007) Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110:1417–1428CrossRefPubMed

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F (2008) EAU guidelines on prostate cancer. Eur Urol 53:68–80CrossRefPubMed

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597CrossRefPubMed

Zagars GK, Pollack A (1997) Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213–221CrossRefPubMed

Perlmutter MA, Lepor H (2008) Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy. Urology 71:501–505CrossRefPubMed

Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B (2008) A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 179:906–910 discussion 910CrossRefPubMed

Langsteger W, Heinisch M, Fogelman I (2006) The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36:73–92CrossRefPubMed

Schmidt GP, Kramer H, Reiser MF, Glaser C (2007) Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top Magn Reson Imaging 18:193–202CrossRefPubMed

10.

Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18:1937–1952CrossRefPubMed

11.

Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P, Fazio F (2004) Diagnosis of local recurrence after radical prostatectomy. BJU Int 93:680–688CrossRefPubMed

12.

Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, Teillac P, Tunn UW (2004) Management of prostate-specific antigen relapse in prostate cancer: a European consensus. Int J Clin Pract 58:382–390CrossRefPubMed

13.

Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, Ferrigni RG (1994) Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 69:613–619PubMed

14.

vander Kooy MJ, Pisansky TM, Cha SS, Blute ML (1997) Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 49:65–70CrossRefPubMed

15.

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041CrossRefPubMed

16.

Siddiqui SA, Mynderse LA, Zincke H, Hoffmann NE, Lobo JR, Wilson TM, Kawashima A, Davis BJ, Blute ML (2007) Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience. Urology 70:80–85CrossRefPubMed

17.

Hayashi M, Shinmei S, Asano K (2007) Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy. Int J Urol 14:1048–1050CrossRefPubMed

18.

Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325–1332CrossRefPubMed

19.

Wasserman NF, Kapoor DA, Hildebrandt WC, Zhang G, Born KM, Eppel SM, Reddy PK (1992) Transrectal US in evaluation of patients after radical prostatectomy. Part I. Normal postoperative anatomy. Radiology 185:361–366PubMed

20.

Wasserman NF, Kapoor DA, Hildebrandt WC, Zhang G, Born KM, Eppel SM, Reddy PK (1992) Transrectal US in evaluation of patients after radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer. Radiology 185:367–372PubMed

21.

Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219:432–439PubMed

22.

Sella T, Schwartz LH, Hricak H (2006) Retained seminal vesicles after radical prostatectomy: frequency, MRI characteristics, and clinical relevance. AJR Am J Roentgenol 186:539–546CrossRefPubMed

23.

Deliveliotis C, Manousakas T, Chrisofos M, Skolarikos A, Delis A, Dimopoulos C (2007) Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J Urol 25:309–313CrossRefPubMed

24.

Sudakoff GS, Smith R, Vogelzang NJ, Steinberg G, Brendler CB (1996) Color Doppler imaging and transrectal sonography of the prostatic fossa after radical prostatectomy: early experience. AJR Am J Roentgenol 167:883–888PubMed

25.

Tamsel S, Killi R, Apaydin E, Hekimgil M, Demirpolat G (2006) The potential value of power Doppler ultrasound imaging compared with grey-scale ultrasound findings in the diagnosis of local recurrence after radical prostatectomy. Clin Radiol 61:325–330 discussion 323–324CrossRefPubMed

26.

Drudi FM, Giovagnorio F, Carbone A, Ricci P, Petta S, Cantisani V, Ferrari FS, Marchetti F, Passariello R (2006) Transrectal colour Doppler contrast sonography in the diagnosis of local recurrence after radical prostatectomy—comparison with MRI. Ultraschall Med 27:146–151CrossRefPubMed

27.

Allen SD, Thompson A, Sohaib SA (2008) The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging. Eur Radiol 18:1281–1291CrossRefPubMed

28.

Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385CrossRefPubMed

29.

Pucar D, Sella T, Schoder H (2008) The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 18:87–97CrossRefPubMed

30.

Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, Gualdi GF (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 190:1187–1192CrossRefPubMed

31.

Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19:761–769CrossRefPubMed

32.

Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54:589–600CrossRefPubMed

33.

Casciani E, Bertini L, Gualdi G (2008) Re: Alessandro Sciarra, Valeria Panebianco, Stefano Salciccia, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. doi:10.1016/j.eururo.2007.12.034 PubMed

34.

Miralbell R, Vees H, Lozano J, Khan H, Molla M, Hidalgo A, Linero D, Rouzaud M (2007) Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 67:356–361PubMed

35.

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Moller P, Wiegel T, Kuefer R, Gschwend JE (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100:786–793CrossRefPubMed

36.

Reske SN, Blumstein NM, Glatting G (2008) [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35:9–17CrossRefPubMed

37.

Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovo MG (2006) [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387–1398CrossRefPubMed

38.

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R (2007) 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99:1415–1420CrossRefPubMed

39.

Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A (2003) Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929–943PubMed

40.

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMed

41.

Cox JD, Kline RW (1983) The lack of prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol 1:237–242PubMed

42.

Zapatero A, Minguez R, Nieto S, Martin de Vidales C, Garcia-Vicente F (2009) Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? Eur Urol. doi:10.1016/j.eururo.2008.04.076 PubMed

43.

Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179:1368–1373; discussion 1373CrossRefPubMed

44.

Touma NJ, Izawa JI, Chin JL (2005) Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 173:373–379CrossRefPubMed

45.

Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, Von Eschenbach AC, Pisters LL (2002) Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 20:2664–2671CrossRefPubMed

46.

Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB (2001) Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 165:1937–1941; discussion 1941–1932CrossRefPubMed

47.

Ismail M, Ahmed S, Kastner C, Davies J (2007) Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 100:760–764CrossRefPubMed

48.

Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL (1999) Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 162:398–402CrossRefPubMed

49.

Robinson JW, Donnelly BJ, Coupland K, Siever JE, Saliken JC, Scott C, Brasher PM, Ernst DS (2006) Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol Oncol 24:472–486PubMed

50.

Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, Larson TR, Wilkes MM, Navickis RJ (1999) Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53:2–10CrossRefPubMed

51.

Beyer DC (1999) Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 54:880–883CrossRefPubMed

52.

Nguyen PL, Chen MH, D’Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW (2007) Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 110:1485–1492CrossRefPubMed

53.

Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol. doi:10.1016/j.eururo.2008.04.091 PubMed

54.

Poissonnier L, Murat FJ, Belot A, Bouvier R, Rabilloud M, Rouviere O, Chapelon JY, Gelet A (2008) Locally recurrent prostatic adenocarcinoma after exclusive radiotherapy: results of high intensity focused ultrasound. Prog Urol 18:223–229CrossRefPubMed

55.

Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M (2008) The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 102:786–792CrossRefPubMed

56.

Rouviere O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY, Gelet A, Lyonnet D (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor—correlation with biopsy findings. Urology 63:922–927CrossRefPubMed

57.

Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M 3rd, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448CrossRefPubMed

58.

Sala E, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, Ishill N, Zelefsky MJ, Eastham JA, Hricak H (2006) Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 238:176–183CrossRefPubMed

59.

Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy—initial experience. Radiology 236:545–553CrossRefPubMed

60.

Kim CK, Park BK, Lee HM (2009) Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 29:391–397CrossRefPubMed

61.

Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430PubMed

62.

Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M 3rd (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055CrossRefPubMed

63.

Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, Scardino PT, Zelefsky MJ (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69:62–69PubMed

64.

Albrecht S, Buchegger F, Soloviev D, Zaidi H, Vees H, Khan HG, Keller A, Bischof Delaloye A, Ratib O, Miralbell R (2007) (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 34:185–196CrossRefPubMed

65.

Jana S, Blaufox MD (2006) Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 36:51–72CrossRefPubMed

66.

Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W (2006) Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8:43–48CrossRefPubMed

67.

Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51:381–387CrossRefPubMed

68.

Uchida T, Illing RO, Cathcart PJ, Emberton M (2006) To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 98:537–539CrossRefPubMed

69.

Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF (2009) High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int. doi:10.1111/j.1464-410X.2009.08518.x PubMed

70.

Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B (2006) Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 24:585–590CrossRefPubMed

71.

Pasticier G, Chapet O, Badet L, Ardiet JM, Poissonnier L, Murat FJ, Martin X, Gelet A (2008) Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology 72:1305–1309CrossRefPubMed

72.

Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D (2007) Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol 63:317–327CrossRefPubMed

73.

Rouviere O, Mege-Lechevallier F, Chapelon JY, Gelet A, Bouvier R, Boutitie F, Lyonnet D (2006) Evaluation of color doppler in guiding prostate biopsy after HIFU ablation. Eur Urol 50:490–497CrossRefPubMed

74.

Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mege-Lechevallier F, Gelet A, Chapelon JY, Lyonnet D, Rouviere O (2008) MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results. J Radiol 89:571–577CrossRefPubMed

75.

Cirillo S, Petracchini M, D’Urso L, Dellamonica P, Illing R, Regge D, Muto G (2008) Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. BJU Int 102:452–458CrossRefPubMed

76.

Kim CK, Park BK, Lee HM, Kim SS, Kim E (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190:1180–1186CrossRefPubMed

77.

Rouviere O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mege-Lechevallier F, Rabilloud M, Chapelon JY, Lyonnet D (2009) Prostate cancer HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol. doi:10.1007/s00330-009-1520-5

78.

Hepel JT, MacAusland SG, Long JP, Wazer DE, DiPetrillo T (2008) Intensity-modulated radiotherapy of the prostate after cryotherapy: initial experience. Urology 72:1310–1314; discussion 1314CrossRefPubMed

79.

Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR (1996) Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48:594–599CrossRefPubMed

80.

Kalbhen CL, Hricak H, Shinohara K, Chen M, Parivar F, Kurhanewicz J, Vigneron DB, Carroll PR (1996) Prostate carcinoma: MR imaging findings after cryosurgery. Radiology 198:807–811PubMed

81.

Carey B, Swift S (2007) The current role of imaging for prostate brachytherapy. Cancer Imaging 7:27–33CrossRefPubMed

82.

Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM (2006) Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65:1487–1493PubMed

83.

Tharp M, Hardacre M, Bennett R, Jones WT, Stuhldreher D, Vaught J (2008) Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7:231–236CrossRefPubMed

84.

Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M (2001) Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 219:817–821PubMed

85.

Bloch BN, Lenkinski RE, Helbich TH, Ngo L, Oismueller R, Jaromi S, Kubin K, Hawliczek R, Kaplan ID, Rofsky NM (2007) Prostate postbrachytherapy seed distribution: comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: initial experience. Int J Radiat Oncol Biol Phys 69:70–78PubMed

86.

Pickett B, Ten Haken RK, Kurhanewicz J, Qayyum A, Shinohara K, Fein B, Roach M 3rd (2004) Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 59:665–673PubMed

Titel: Imaging of prostate cancer local recurrences: why and how?
verfasst von: Olivier Rouvière
Thierry Vitry
Denis Lyonnet
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 5/2010
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-009-1647-4

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Imaging of prostate cancer local recurrences: why and how?

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Diffusion-weighted MR neurography of the sacral plexus with unidirectional motion probing gradients

Rotator cuff tears: should abduction and external rotation (ABER) positioning be performed before image acquisition? A CT arthrography study

Coronal reconstruction of unenhanced abdominal CT for correct ureteral stone size classification

Peri-infarct dysfunction in post-myocardial infarction: assessment of 3-T tagged and late enhancement MRI

Prospectively gated axial CT coronary angiography: comparison of image quality and effective radiation dose between 64- and 256-slice CT

Aortic stiffness is associated with cardiac function and cerebral small vessel disease in patients with type 1 diabetes mellitus: assessment by magnetic resonance imaging

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie